{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/zh-Hant/reddit/r/investing/comments/ouj7jl/global_coronavirus_covid19_vaccine_market/","result":{"data":{"site":{"siteMetadata":{"title":"国外股市热门","author":"Buzzing.cc","description":"用中文浏览国外股票社区里的热门讨论","keywords":["buzzing","美股","股票","股市"],"siteUrl":"https://stocks.buzzing.cc","telegram":"@stocks_top","iconUrl":"https://stocks.buzzing.cc/avatar.png","defaultSocialImageUrl":null,"social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true},{"name":"Charlie Bilello's twitter","url":"https://twitter.com/charliebilello","external":true},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null}],"disqus":null,"utterances":null,"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","keywords":["buzzing","stocks","U.S. stocks"],"locale":"en","social":{"name":null,"url":null,"external":null},"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null}]},{"title":"國外股市熱門","description":"用中文瀏覽國外股票社區裡的熱門討論","keywords":["buzzing","美股","股票","股市"],"locale":"zh-Hant","social":null,"menuLinks":[{"name":"每週精選","url":"/zh-Hant/issues","external":null}]},{"title":"米国株式市場人気の話し合います","description":"人気の米国株式市場の話し合いまを日本語で閲覧","keywords":["buzzing","米国株式市場"],"locale":"ja","social":null,"menuLinks":[]}]}},"blogPost":{"id":"RedditPost-6e34369a-0890-5f26-9480-8320e1647338","excerpt":"Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The \"Global Coronavirus Vaccine\nMarket, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By\nProduct Type, By Route of Administration, By Patient Type, By End User, By\nRegion, Competition Forecast & Opportunities, 2026\" report has been…","body":"<!-- SC_OFF --><div class=\"md\"><p>Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The &quot;Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast &amp; Opportunities, 2026&quot; report has been added to <strong>ResearchAndMarkets.com&#39;s</strong> offering.  </p>\n\n<p>The Global Coronavirus Vaccine Market is expected to grow at a robust rate in value terms to reach USD 91325.46 million by the end of 2021.</p>\n\n<p>The ongoing pandemic novel coronavirus disease (COVID-19) is caused due to SARS-COV-2 and generally spreads from animals to humans and then from humans to humans.  </p>\n\n<p>The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period. The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe. This has increased the need to protect the world from the virus, thereby increased sales of coronavirus vaccine through 2026.</p>\n\n<p>Furthermore, increasing research and development activities by various pharmaceutical &amp; biotechnology players for the development of potential vaccines is anticipated to foster the market growth. According to WHO, there are more than 70 coronavirus vaccines under development by different companies and organizations.  </p>\n\n<p>Currently, mRNA-based vaccine named Moderna COVID-19 Vaccine (mRNA-1273), adenovirus-based vaccine named COVID-19 Vaccine AstraZeneca (AZD1222) also known as Covishield in India and Sputnik V which constitutes recombinant adenovirus vaccine which is developed by Gamaleya Research Institute, Russia are being used for vaccination among adults.</p>\n\n<p>The vaccine developed by Moderna, Inc., Pfizer Inc., AstraZeneca PLC are leading the race and is currently administered to entire population. T-COVIDTM, AdCOVID and COVI-VAC are intranasal COVID-19 vaccines which are under pre-clinical and phase 1 trials.  </p>\n\n<p>The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region. Based on infection type, the market can be categorized into SARS-CoV-2, SARS-CoV and MERS-CoV. The SARS-CoV-2 segment is expected to dominate the market since this infection or virus is the primary cause of the pandemic.  </p>\n\n<p>Regionally, the Global Coronavirus Vaccine Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East &amp; Africa. Among these, Asia-Pacific is expected to witness significant growth during the forecast period in the overall coronavirus vaccine market.  </p>\n\n<p>Major companies are developing advanced technologies and launching new services to stay competitive in the market. Other competitive strategies include mergers &amp; acquisitions and new product developments.</p>\n\n<p><strong>Major players include</strong></p>\n\n<ul>\n<li>Moderna, Inc</li>\n<li>Pfizer Inc</li>\n<li>Johnson &amp; Johnson SA</li>\n<li>Sinopharm Group Company Ltd</li>\n<li>AstraZeneca PLC</li>\n<li>Serum Institute of India Pvt Ltd</li>\n<li>Bharat Biotech International Ltd</li>\n<li>Sinovac Biotech Ltd</li>\n<li>Sanofi SA</li>\n<li>GlaxoSmithKline PLC</li>\n<li>Novavax, Inc</li>\n<li>Airway Therapeutics, Inc</li>\n<li>Cadila Healthcare Ltd</li>\n<li>CanSino Biologics Inc</li>\n<li>Mitsubishi Chemical Holdings Corporation</li>\n<li>Eubiologics Co Ltd</li>\n<li>United Biomedical Inc</li>\n<li>Merck &amp; Co, Inc</li>\n<li>CureVac NV</li>\n<li>Inovio Pharmaceuticals, Inc</li>\n</ul>\n\n<p><strong>Report Scope:</strong></p>\n\n<p><strong>Years considered for this report:</strong></p>\n\n<ul>\n<li>Base Year: 2020</li>\n<li>Estimated Year: 2021</li>\n<li>Forecast Period: 2022-2026</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By Infection Type:</strong></p>\n\n<ul>\n<li>SARS-CoV-2</li>\n<li>SARS-CoV</li>\n<li>MERS-CoV</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By Vaccine Type:</strong></p>\n\n<ul>\n<li>Virus Vaccine</li>\n<li>Viral Vector Vaccine</li>\n<li>Nucleic Acid Vaccine</li>\n<li>Protein Based Vaccine</li>\n<li>Others</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By Product Type:</strong></p>\n\n<ul>\n<li>Monovalent Vaccine</li>\n<li>Multivariant Vaccine</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By Route of Administration:</strong></p>\n\n<ul>\n<li>Intramuscular</li>\n<li>Oral</li>\n<li>Intranasal</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By Patient Type:</strong></p>\n\n<ul>\n<li>Adult</li>\n<li>Pediatric</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By End-User:</strong></p>\n\n<ul>\n<li>Hospitals</li>\n<li>Clinics</li>\n<li>Research Institutes</li>\n<li>Others</li>\n</ul>\n\n<p><strong>Global Coronavirus Vaccine Market, By Region:</strong></p>\n\n<ul>\n<li>North America</li>\n<li>United States</li>\n<li>Mexico</li>\n<li>Canada</li>\n<li>Europe</li>\n<li>United Kingdom</li>\n<li>Germany</li>\n<li>France</li>\n<li>Italy</li>\n<li>Spain</li>\n<li>Asia-Pacific</li>\n<li>China</li>\n<li>India</li>\n<li>Singapore</li>\n<li>Japan</li>\n<li>South Korea</li>\n<li>Hong Kong</li>\n<li>Australia</li>\n<li>Thailand</li>\n<li>South America</li>\n<li>Brazil</li>\n<li>Argentina</li>\n<li>Colombia</li>\n<li>Middle East &amp; Africa</li>\n<li>UAE</li>\n<li>Saudi Arabia</li>\n<li>Kuwait</li>\n<li>South Africa</li>\n</ul>\n\n<p><a href=\"https://ceo.ca/@nasdaq/global-coronavirus-covid-19-vaccine-market-research\">https://ceo.ca/@nasdaq/global-coronavirus-covid-19-vaccine-market-research</a></p>\n</div><!-- SC_ON -->","slug":"/reddit/r/investing/comments/ouj7jl/global_coronavirus_covid19_vaccine_market/","title":"Global Coronavirus (COVID-19) Vaccine Market Research Report 2021: Market is Expected to Grow at a Robust Rate to Reach $91.3 Billion","tags":["investing","reddit"],"date":"July 30, 2021","dateISO":"2021-07-30T14:18:56.000Z","datetime":"2021-07-30 14:18","image":null,"imageAlt":null,"socialImage":null,"__typename":"SocialMediaPost","thirdPartyId":"6e34369a-0890-5f26-9480-8320e1647338","provider":"Reddit","url":"https://www.reddit.com/r/investing/comments/ouj7jl/global_coronavirus_covid19_vaccine_market/","originalUrl":"https://www.reddit.com/r/investing/comments/ouj7jl/global_coronavirus_covid19_vaccine_market/","imageRemote":null,"video":null,"channel":"investing","channelUrl":"https://www.reddit.com/r/investing","author":"razsujemwn","authorUrl":"https://www.reddit.com/user/razsujemwn","authorImage":null,"authorImageRemote":null,"authorSlug":"razsujemwn","score":502,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"localize":[{"title":"コロナウイルス（COVID-19）ワクチンの世界市場調査報告書2021年版。市場は堅調な伸びを示し、913億ドルに達する見込み","the_new_excerpt":"Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- 「世界のコロナウイルスワクチンの\n世界のコロナウイルスワクチン市場、感染タイプ別（SARS-CoV-2、SARS-CoV、MERS-CoV）、ワクチンタイプ別、製品タイプ別。\nワクチンタイプ別、製品タイプ別、投与経路別、患者タイプ別、エンドユーザー別、地域別\n地域別、競合予測と機会、2026年」レポートが発行されました...","locale":"ja"},{"title":"2021年全球冠状病毒（COVID-19）疫苗市场研究报告。市场预计将以强劲的速度增长，达到913亿美元的规模","the_new_excerpt":"都柏林，2021年7月30日（GLOBE NEWSWIRE）--《全球冠状病毒疫苗\n市场，按感染类型（SARS-CoV-2、SARS-CoV、MERS-CoV），按疫苗类型，按\n产品类型、给药途径、患者类型、终端用户、地区\n地区，竞争预测和机会，2026年 \"报告已被...","locale":"zh"},{"title":"2021年全球冠狀病毒（COVID-19）疫苗市場研究報告。市場預計將以強勁的速度增長，達到913億美元的規模","the_new_excerpt":"都柏林，2021年7月30日（GLOBE NEWSWIRE）--《全球冠狀病毒疫苗\n市場，按感染類型（SARS-CoV-2、SARS-CoV、MERS-CoV），按疫苗類型，按\n產品類型、給藥途徑、患者類型、終端用戶、地區\n地區，競爭預測和機會，2026年 \"報告已被...","locale":"zh-Hant"}]}},"previous":{"id":"TweetPost-1420918305284632581","excerpt":"","slug":"/tweet/1420918305284632581","title":"NYC IS BACK!\n https://t.co/OfbaIAgDWU","date":"July 30, 2021","__typename":"SocialMediaPost","provider":"Twitter","parent":{"localize":[{"locale":"ja","full_text":"NYC IS BACK!\n https://t.co/OfbaIAgDWU","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh","full_text":"纽约市回来了!\n https://t.co/OfbaIAgDWU","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh-Hant","full_text":"紐約市回來了!\n https://t.co/OfbaIAgDWU","quoted_status_full_text":null,"retweeted_status_full_text":null}]}},"next":{"id":"RedditPost-09927129-7701-5e32-b7b2-3377d1e85447","excerpt":"The Ark Innovation ETF ARKK, +0.21%, the flagship fund of Cathie Wood's Ark\nInvestment Management, purchased nearly 1.3 million shares of Robinhood Markets\nHOOD, -8.37% during its first day of trade, worth roughly $45 million. Robinhood\nshares slumped 8% as the initial public offering, targeted to…","slug":"/reddit/r/stocks/comments/ouk7fb/ark_innovation_etf_bought_45_million_worth_of/","title":"Ark Innovation ETF bought $45 million worth of Robinhood on first day of trade","__typename":"SocialMediaPost","date":"July 30, 2021","provider":"Reddit","parent":{"localize":[{"title":"アーク・イノベーションETFは、取引初日に4500万ドル分のRobinhoodを購入しました。","the_new_excerpt":"キャシー・ウッドのアーク・インベストメント・マネジメントの旗艦ファンドであるアーク・イノベーションETF ARKK, +0.21%は、ロビンの株式を130万株近く購入しました。\nインベストメント・マネジメントが、ロビンフッド・マーケッツの約130万株を購入しました。\nHOOD, -8.37% 初日の取引で、およそ4,500万ドル相当を購入しました。ロビンフッド\n株は8％下落しましたが、これは新規株式公開のためのものです。","locale":"ja"},{"title":"方舟创新ETF交易首日买入价值4500万美元的Robinhood","the_new_excerpt":"方舟创新ETF ARKK, +0.21%，是凯茜-伍德的方舟投资管理公司的旗舰基金。\n投资管理公司，购买了近130万股Robinhood Markets\nHOOD, -8.37%，在其第一天的交易中，价值约为4500万美元。罗宾汉\n股价暴跌8%，因为首次公开募股的目标是...","locale":"zh"},{"title":"方舟創新ETF交易首日買入價值4500萬美元的Robinhood","the_new_excerpt":"方舟創新ETF ARKK, +0.21%，是凱茜-伍德的方舟投資管理公司的旗艦基金。\n投資管理公司，購買了近130萬股Robinhood Markets\nHOOD, -8.37%，在其第一天的交易中，價值約爲4500萬美元。羅賓漢\n股價暴跌8%，因爲首次公開募股的目標是...","locale":"zh-Hant"}]}}},"pageContext":{"basePath":"/","pageType":"detail","id":"RedditPost-6e34369a-0890-5f26-9480-8320e1647338","previousId":"TweetPost-1420918305284632581","nextId":"RedditPost-09927129-7701-5e32-b7b2-3377d1e85447","maxWidth":1024,"siteMetadata":null,"locale":"zh-Hant","hrefLang":"zh-Hant","originalPath":"/reddit/r/investing/comments/ouj7jl/global_coronavirus_covid19_vaccine_market/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2744905544","3280999885"]}